Literature DB >> 28898227

Challenges in the gene therapy commercial ecosystem.

Rahul Kapoor1, Thomas Klueter2, James M Wilson3.   

Abstract

Year:  2017        PMID： 28898227     DOI： 10.1038/nbt.3931

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

Review 1.  Progress and problems with the use of viral vectors for gene therapy.

Authors:  Clare E Thomas; Anja Ehrhardt; Mark A Kay
Journal:  Nat Rev Genet       Date:  2003-05       Impact factor: 53.242

2.  It's time for gene therapy to get disruptive!

Authors:  James M Wilson
Journal:  Hum Gene Ther       Date:  2012-01       Impact factor: 5.695

3.  Monoclonal antibody successes in the clinic.

Authors:  Janice M Reichert; Clark J Rosensweig; Laura B Faden; Matthew C Dewitz
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

4.  The special case of gene therapy pricing.

Authors:  Troyen A Brennan; James M Wilson
Journal:  Nat Biotechnol       Date:  2014-09       Impact factor: 54.908
  4 in total
  2 in total

1.  Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition.

Authors:  Na Kong; Wei Tao; Xiang Ling; Junqing Wang; Yuling Xiao; Sanjun Shi; Xiaoyuan Ji; Aram Shajii; Silvia Tian Gan; Na Yoon Kim; Dan G Duda; Tian Xie; Omid C Farokhzad; Jinjun Shi
Journal:  Sci Transl Med       Date:  2019-12-18       Impact factor: 17.956

2.  Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy.

Authors:  Yuling Xiao; Jiang Chen; Hui Zhou; Xiaodong Zeng; Zhiping Ruan; Zhangya Pu; Xingya Jiang; Aya Matsui; Lingling Zhu; Zohreh Amoozgar; Dean Shuailin Chen; Xiangfei Han; Dan G Duda; Jinjun Shi
Journal:  Nat Commun       Date:  2022-02-09       Impact factor: 14.919
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.